Degron Therapeutics extends Series A as DEG6498 enters the harder phase of cancer drug validation
Molecular glue funding is back, but clinic data remain thin. Degron’s HuR bet now faces the proof burden in solid tumors.
HBM7004 FDA clearance gives Harbour BioMed a fresh solid tumor immunotherapy test
Solid tumor T-cell engagers still face safety limits. Harbour BioMed’s HBM7004 now tests whether B7-H4 can widen that window.
Can Forlong Biotechnology’s FL115 poster at ASCO 2026 move the IL-15 story from scientific promise toward clinical relevance?
Forlong Biotechnology brings FL115 to ASCO 2026 with first-in-human solid tumor data. Read why the IL-15 story could matter beyond the poster.
FDA IND clearance propels ViroMissile’s IDOV-Immune into major U.S. cancer centers
ViroMissile expands its IDOV-Immune Phase I trial to U.S. sites after FDA IND clearance. Discover what this means for systemic oncolytic therapy.